Cadrenal Therapeutics, Inc. CVKD
for life-threatening immune and thrombotic conditions. As a result of our acquisition of a 12-lipoxygenase ("12-LOX") platform
of assets in December 2025 (as described in more detail below), we transitioned our primary strategic focus to the development of CAD-1005
for the treatment of immune-mediated and thrombotic disorders. Our lead product candidate, CAD-1005, is a first-in-class selective 12-LOX
inhibitor being developed to treat heparin-induced thrombocytopenia ("HIT"), a deadly immune-mediated thrombotic disorder.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2007 |
|---|---|---|---|---|---|
| Cost of revenue | — | — | $220.1K | — | $220.1K |
| R&D | $4.1M | $4.2M | $4.1M | $3.0M | — |
| SG&A | $9.4M | $6.8M | $3.5M | $2.3M | — |
| Total operating expenses | $13.5M | $11.0M | $7.6M | $2.7M | — |
| Operating income | -$13.5M | -$11.0M | -$7.6M | -$2.7M | — |
| Interest expense | — | — | $3.5K | $40.2K | — |
| Net income | -$13.2M | -$10.7M | -$8.4M | -$6.7M | — |
| EPS, basic | -6.64 | -8.73 | -9.29 | -0.85 | — |
| EPS, diluted | -6.64 | -8.73 | -9.29 | -0.85 | — |
| Shares, diluted (wtd. avg.) | 2.0M | 1.2M | 899,465 | 7.9M | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2007 |
|---|---|---|---|---|---|
| Cash and equivalents | $4.0M | $10.0M | $8.4M | $32.6K | — |
| Total current assets | $4.3M | $10.1M | $8.5M | $727.6K | — |
| Property, plant and equipment | $5.2K | $6.9K | $2.3K | $1.0K | — |
| Total assets | $4.3M | $10.1M | $8.5M | $778.2K | — |
| Accounts payable | $650.7K | $1.5M | $167.3K | $404.9K | — |
| Short-term debt | — | — | — | $597.1K | — |
| Total current liabilities | $1.6M | $2.7M | $826.9K | $1.3M | — |
| Total liabilities | $1.6M | $2.7M | $826.9K | $6.3M | — |
| Retained earnings | -$39.0M | -$25.7M | -$15.1M | -$6.7M | — |
| Total equity | $2.7M | $7.4M | $7.7M | -$5.6M | — |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2007 |
|---|---|---|---|---|---|
| Operating cash flow | -$12.6M | -$7.4M | -$3.5M | -$1.2M | — |
| Depreciation and amortisation | $6.9K | $1.9K | $2.0K | $1.3K | — |
| Stock-based compensation | $1.9M | $1.4M | $710.4K | $928.0K | — |
| Capital expenditure | $5.1K | $6.5K | $3.3K | $2.3K | — |
| Investing cash flow | -$5.1K | -$6.5K | -$3.3K | -$2.3K | — |
| Financing cash flow | $6.6M | $9.0M | $11.9M | $1.2M | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001213900-26-036946.
Plot the figures US dollars
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2007 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Net income | — | -$6.7M | -$8.4M | -$10.7M | -$13.2M |
Recent filings and events
- Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
- Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
- Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
- Regulation FD disclosure Item 7.01
- Other event Item 8.01
- Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
- Officer or director change Item 5.02
- Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
- Unregistered share sale Shares issued outside a registered offering. Dilution, and for a small company often the way it is funded. Item 3.02
- Other event Item 8.01
- Officer or director change Item 5.02
- Regulation FD disclosure Item 7.01
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| LLY | ELI LILLY & Co | $1.20T | 55.5x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $635.76B | 23.9x | 6.0% |
| ABBV | AbbVie Inc. | $504.76B | 121.0x | 8.6% |
| MRK | Merck & Co., Inc. | $358.41B | 20.0x | 1.3% |
| ABT | ABBOTT LABORATORIES | $180.63B | 27.9x | 5.7% |
| PFE | PFIZER INC | $171.16B | 22.1x | -1.6% |
| VRTX | VERTEX PHARMACEUTICALS INC / MA | $132.80B | 34.2x | 8.9% |
| BMY | BRISTOL MYERS SQUIBB CO | $125.59B | 17.8x | -0.2% |